RB0 Stock Chart & Stats
€7.95
-€0.30(-3.50%)
At close: 4:00 PM EDT
€7.95
-€0.30(-3.50%)
Day’s Range― - ―
52-Week Range€4.73 - €13.60
Previous CloseN/A
Volume0.00
Average Volume (3M)53.00
Market Cap
€434.15M
Enterprise Value€779.85
Total Cash (Recent Filing)€105.52M
Total Debt (Recent Filing)€68.95M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
Nov 11, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.79
Shares Outstanding66,013,190
10 Day Avg. Volume0
30 Day Avg. Volume53
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€19.31Price Target Upside142.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.84
Revenue Forecast (FY)€144.22M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthThe near-doubling of TTM revenue shows that REGENXBIO is converting its platform and partnering activities into materially greater reported sales. Although profitability remains unproven, stronger revenue provides a broader base for funding development and could improve operating leverage as programs advance.
Late-stage Retinal CollaborationAdvancing the diabetic retinopathy program into a Phase IIb/III trial demonstrates meaningful clinical and commercial progress within the retinal pipeline. The $100 million milestone also validates partner commitment and supplies substantial development funding while preserving potential future collaboration economics.
Board Strategic ExpertiseAdding an independent director with capital markets and corporate strategy experience may strengthen oversight as REGENXBIO moves toward a more commercially oriented organization. Board succession and committee changes provide relevant governance support for managing a late-stage pipeline and potential global launch plans.
Bears Say
RGX-121 Clinical HoldThe FDA clinical hold disrupts a major Hunter Syndrome program and management does not expect to resubmit its BLA in the near term. Extended monitoring and data analysis may delay development, reduce near-term pipeline contribution, and increase reliance on other candidates to sustain strategic momentum.
Persistent Operating LossesLarge operating and net losses indicate that REGENXBIO has not yet established sustainable earnings from its gene therapy platform. Even with recent revenue improvement, continued losses leave future financial performance dependent on successful clinical execution, partnering, and eventual commercialization.
Leverage And Cash BurnHigh leverage combined with deeply negative operating and free cash flow reduces financial flexibility and shows that development spending materially exceeds internally generated cash. Continued burn increases dependence on milestone receipts or additional financing to support operations and advance the pipeline.
RegenXBio News
RB0 FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was €4.73 and its highest was €13.60 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is €434.15M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Nov 11, 2026 which is in 41 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Aug 06, 2026. The company reported €0.38 earnings per share for the quarter, beating the consensus estimate of €0.07 by €0.31.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -1.07.
How many shares outstanding does RegenXBio have?
RegenXBio has 66,013,190 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of €0.38 in its last earnings report, beating expectations of €0.07. Following the earnings report the stock price went up 3.939%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in DE:RB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€19.31 (142.96% Upside)
€19.31 (142.96% Upside)
Blogger Sentiment
Bullish
DE:RB0 Sentiment 82%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth €833.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-33.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
RegenXBio
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
RB0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all DE:RB0 earnings summariesRB0 Stock 12 Month Forecast
Average Price Target
€19.31
▲(142.96% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―